Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR1 | P21817 | 9/20 | 0.92 |
| ▸ | AURKA | O14965 | 1/20 | 0.67 |
| ▸ | EGFR | P00533 | 1/20 | 0.67 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.67 |
| ▸ | CDK4 | P11802 | 1/20 | 0.67 |
| ▸ | CCND1 | P24385 | 1/20 | 0.67 |
| ▸ | FLT3 | P36888 | 1/20 | 0.67 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.67 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.67 |
| ▸ | FKBP1A | P62942 | 7/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bastadin 20 SCHEMBL6796056 | 0.89 | AURKA (0.77) | RYR1AURKAEGFRERBB2CDK4 | |
| SCHEMBL6805004 | 0.89 | AURKA (0.77) | RYR1AURKAEGFRERBB2CDK4 | |
| SCHEMBL31443844 | 0.46 | PARP10 (0.56) | — | |
| SCHEMBL20365680 | 0.46 | RYR1 (0.55) | RYR1FKBP1A | |
| SCHEMBL7977984 | 0.44 | TUBB4A (0.60) | AURKACDK4CCND1FLT3AURKB | |
| SCHEMBL7262152 | 0.43 | CRBN (0.46) | — | |
| SCHEMBL2983127 | 0.43 | FABP6 (0.67) | — | |
| SCHEMBL3727752 | 0.43 | PARP10 (0.42) | — | |
| SCHEMBL3727751 | 0.43 | PARP10 (0.42) | — | |
| SCHEMBL31597716 | 0.43 | FABP6 (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009141627-A1 | TREATING NIEMANN-PICK DISEASE TYPE C AND RELATED DISORDERS BY ELEVATING INTRACELLULAR CALCIUM | ISIS INNOVATION LIMITED (GB) | 2009-11-26 | — | — | WO | claimed |
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FOUNTAIN THERAPEUTICS INC (US) | 2024-05-16 | — | — | US | disclosed |
| US-6734211-B1 | FOR STIMULATING NERVE CELL GROWTH IN A SUBJECT COMPRISING ADMINISTERING TO THE SUBJECT A BASTADIN COMPOUND OR ITS ANALOGS | OREGON HEALTH & SCIENCES UNIVERSITY | 2004-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FGFR1, FRS2, FGFR2 | RYR1 2730/4885AURKA 2742/4885EGFR 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.